Medication info
Sebion 5/40mg

Sebion 5/40mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.944mg / 1 tabletOlmesartan Medoxomil›40mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets (10 tablets/PTP x 3)
Approval status
Active

MFDS item code 201404732 · Approved 2014.10.15 · Insurance code 657805430

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60 mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not be administered this medicine, under Precautions for Use.) ∘Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine and Olmesartan Medoxomil are medications used in patients with essential hypertension when blood pressure is not adequately controlled by monotherapy. These drugs work by dilating blood vessels, lowering blood pressure, and reducing the burden on the heart and blood vessels. This helps decrease the risk of complications associated with hypertension. Proper blood pressure control is vital for the prevention of cardiovascular diseases, and these medications are used to effectively manage patients' blood pressure. Therefore, monotherapy with Amlodipine or Olmesartan Medoxomil is effectively used in the treatment of essential hypertension.

How to take

Adult dose

This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60 mL/min) is 20 mg once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Caution should be exercised when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not be administered this medicine, under Precautions for Use.) ∘Elderly patients: In general, treatment should be initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and comorbidities should be taken into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately if pregnancy is confirmed. Individuals allergic to any of the ingredients in this medication, as well as those who are pregnant or breastfeeding, those with severe liver impairment, severe aortic stenosis, bile duct obstruction, patients undergoing kidney dialysis, in a state of shock, and certain diabetic patients should not take this medication. Patients with a deficiency of fluids or salts may experience low blood pressure, so their condition should be monitored closely at the beginning of treatment, and appropriate measures should be taken if hypotension occurs. Patients with aortic stenosis need to take special care, as rapid dilation of blood vessels may cause low blood pressure. Patients with severe obstructive coronary artery disease may experience increased risk of angina or myocardial infarction after taking this medication, so caution is advised. This medication should be used with caution in patients with heart failure, and kidney function changes should be closely monitored in patients with impaired kidney function. In patients with liver impairment, this medication may remain in the liver for an extended period, so caution is needed during use. This medication can cause various side effects; symptoms such as dizziness, headache, hypotension, edema, dyspepsia, rash, etc., should prompt immediate consultation with healthcare professionals. Particularly, taking this medication during pregnancy could cause serious problems for the fetus, so women planning for or currently pregnant should consult a doctor. In breastfeeding, this medication may be passed into breast milk and cause adverse reactions in infants, so breastfeeding should be ceased or medication should be stopped. The safety and efficacy of this medication in individuals under 18 years of age have not been established, so it is not recommended. Elderly patients may be more sensitive to the medication due to decreased kidney and liver function, therefore starting with a low dose and proceeding with caution is advised. Overdose may lead to severe hypotension and cardiac issues, so care must be taken not to exceed the prescribed dosage, and any unusual symptoms should prompt immediate medical consultation. This medication should be stored in a tightly sealed container, away from moisture, heat, and direct sunlight, out of reach of children.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • reduced sensation
  • syncope
Show 84 more
  • vertigo
  • palpitations
  • tachycardia
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • indigestion
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • back pain
  • polyuria
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • cerebral infarction exacerbation
  • gum bleeding
  • orthostatic dizziness
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • runny nose
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastritis
  • herpes zoster
  • diplopia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • intestinal vascular edema
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • elevated serum creatinine
  • hyperkalemia
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. It is important to maintain a storage temperature between 1 degree and 30 degrees Celsius (room temperature). Proper storage helps maintain the medication's efficacy and safety.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets (10 tablets/PTP x 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.